Capsule Colonoscopy in Crohn's Disease and Its Correlation With Conventional Colonoscopy and Faecal Calprotectin
Crohn's Disease
About this trial
This is an interventional supportive care trial for Crohn's Disease
Eligibility Criteria
Inclusion Criteria:
- Adults with established diagnosis of CD with ileal, colonic or ileo-colonic disease aged 18-75 years. Gender: both male and female
- Patients of RMH IBD clinic and other specialty clinics where assessment of mucosal healing is clinically indicated this includes: Patients who have had Anti TNF induction therapy 6-12 months prior to commencement of this study AND/OR Patients referred for colonoscopy to assess mucosal disease status with a view to treatment escalation based on the findings.
Exclusion Criteria:
Patients must not:
- Have known/suspected gastrointestinal obstruction
- Have swallowing disorder
- Have a known oesophageal stricture
- Have severe gastroparesis
- Have dementia
- Have a cardiac pacemaker or other implanted medical device
- Have sever cardiac or renal insufficiency
- Have a previous allergy or contraindication to bowel preparation
- Be pregnant
- Prior major abdominal surgery
- Colonoscopy is contraindicated
Sites / Locations
- Royal Melbourne Hospital
Arms of the Study
Arm 1
Other
Anti TNF induction therapy 6-12 months
All subjects will be identified through The Royal Melbourne Hospital's IBD clinic, associated specialty clinics and the colonoscopy waiting list of The Royal Melbourne Hospital. The potential participants who have been commenced on Anti TNF induction therapy 6-12 months prior to commencement of the study will be identified. The potential participants identified in this way will be informed of the project at the time of contact and assessment; in some instances the potential participant will be informed of the project via telephone where subjects are remote. The potential participants will be provided an Ethically-approved information sheet at this time. Consent will be gained at the time of assessment.